Actively Recruiting
Study of Nuvastatic 300 mg Capsules to Reduce Chemotherapy-Related Fatigue in Women With Metastatic Triple-Negative Breast Cancer
Led by Natureceuticals Sdn Bhd · Updated on 2026-08-25
250
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether Nuvastatic 300 mg capsules can reduce cancer-related fatigue in adult female patients with triple-negative metastatic breast cancer who are undergoing first-line chemotherapy. This phase III trial compares Nuvastatic 300 mg capsules to a placebo to assess their effects on fatigue levels and to evaluate the safety and tolerability of Nuvastatic in this patient group. Participants will receive either Nuvastatic 300 mg capsules or placebo capsules, taken three times daily for three cycles lasting 20 days each, totaling approximately 60 days of treatment. They will continue their standard chemotherapy throughout the study. Blood samples will be collected at screening and at the end of treatment to monitor participants health and treatment effects. During the study, participants will complete fatigue assessments and patient diaries following the study protocol. Researchers will measure the reduction in cancer-related fatigue from screening to the end of treatment, about six months. Secondary measures include overall quality of life and functional improvements. The study also includes safety monitoring and follow-up during the entire study period.
CONDITIONS
Brief Title
Nuvastatic® Phase III Trial for Fatigue in Triple-Negative Breast Cancer
Research Team
A
Aman Shah Abdul Majid, MBChB, DPhil
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here